MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Tuesday reported a fourth-quarter loss of $9.1 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the Monrovia, California-based company said it had a loss of 21 cents.
The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share.
The biotech developing antibodies for severe autoimmune/allergic diseases and cancer posted revenue of $6.4 million in the period.
For the year, the company reported net income of $23.6 million, or 56 cents per share, swinging to a profit in the period. Revenue was reported as $87.5 million.
Xencor shares have fallen nearly 6 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $24.85, more than doubling in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XNCR at https://www.zacks.com/ap/XNCR
Keywords: Xencor, Earnings Report